Skip to main content

Targeting leukaemia by modulating hematopoietic stem cell competitiveness

Project description

Targeting leukemic stem cells

Acute myeloid leukemia (AML) remains a devastating disease with less than 30 % of patients surviving five years after diagnosis. The resistance of AML is driven by small subpopulations of leukemic stem cells (LSCs), which survive chemotherapy and elude immune surveillance. LSCs have growth advantages induced by oncogenic mutations but are in many ways similar to healthy hematopoietic stem cells (HSCs). LSCs are located in protective bone marrow niches promoting stemness and therapy resistance and modify these to displace HSCs for their own expansion. The EU-funded Hemstem project explores strategies to target LSCs based on the knowledge of the complex interactions between LSCs and HSCs and provides a rationale for novel treatments.

Call for proposal

ERC-2019-COG
See other projects for this call

Funding Scheme

ERC-COG - Consolidator Grant

Host institution

UNIVERSITAT BASEL
Address
Petersplatz 1
4051 Basel
Switzerland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 984 240

Beneficiaries (1)

UNIVERSITAT BASEL
Switzerland
EU contribution
€ 1 984 240
Address
Petersplatz 1
4051 Basel
Activity type
Higher or Secondary Education Establishments